Welcome GRADE CHEMICAL
0 items$0.00

No products in the cart.

mexican farmapram bars 2 mg genuine farmapram 2 mg or 1 mg

mexican farmapram bars 2 mg

mexican farmapram bars

mexican farmapram bars 2 mg made by IFA is a alprazolam come from mexico under band name ( farmapram xanax bars , mexico farmapram or also mexican bars 2 mg)

THERAPEUTIC INDICATIONS

 Anxiolytic.

mexican farmapram bars is indicated in the treatment of anxiety: Anxiety with symptoms of depression and panic attack (panic attack), states of simple anxiety and associated with other conditions such as: chronic phase of alcohol withdrawal, organic or functional conditions (somatization).

mexican farmapram bars is a triazolobenzodiazepine. The exact mechanism of action has not been established so far. Clinically all benzodiazepines cause a dose-dependent central nervous system depression ranging from minimal disturbances to hypnosis.

mexican farmapram bars 2 mg
mexican farmapram bars 2 mg

After oral administration, alprazolam is rapidly absorbed, reaching serum peaks 1 to 2 hours after administration.

The elimination half-life of mexican farmapram bars is 1 to 15 hours, with urine being the main route of excretion. Like the other benzodiazepines, mexican farmapram bars crosses the placental barrier and is excreted in human milk.

CONTRAINDICATIONS:

mexican farmapram bars is contraindicated in patients with known sensitivity to benzodiazepines, angle-closure glaucoma and myasthenia gravis.

GENERAL PRECAUTIONS:

mexican farmapram bars causes CNS depression, so patients who are
administered it should be warned that the product depresses osteotendinous reflexes, so caution should be used when operating precision vehicles or machinery.

Seizures have been reported when the dose is rapidly decreased or if treatment is abruptly discontinued in some patients receiving recommended or high doses of alprazolam for relatively short periods (1 week to 4 months). For this reason the alprazolam dose should be gradually reduced or withdrawn.

In elderly or debilitated patients, it is recommended that the dose to be used is the lowest and most effective in order to avoid the development of ataxia or over-sedation.

In order to discontinue alprazolam treatment according to good medical practice the dose should be reduced slowly. It is suggested that the daily dose be decreased by 0.5 mg every 3 days.

Some patients may require a lower dose decrease.

Symptoms have been reported from withdrawal following rapid or abrupt discontinuation of benzodiazepines including alprazolam.

These have ranged from mild dysphoria and insomnia to a major syndrome which may include abdominal cramps, vomiting, sweating, fear and seizures.

Alprazolam administration to severely depressed or potentially suicidal patients should be done with appropriate precautions.

With the administration of farmapram xanax bars, the usual precautions should be observed in patients compromised in their kidney or liver function.

It is not recommended in patients with a primary diagnosis of schizophrenia.

Although no withdrawal effects have been observed in patients who abruptly discontinued farmapram xanax bars after 6 months of therapy, such withdrawal symptoms have been reported as a consequence of the abrupt discontinuation of other benzodiazepines. Individuals inclined to drug abuse such as alcoholics or drug addicts should be closely monitored if they receive benzodiazepine treatment in view of their predisposition to habituation and dependence.

RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING:

The use of this product in pregnancy increases the risk of birth defects. As a general rule, mothers are recommended not to breastfeed while
receiving farmapram xanax bars since, like the rest of the benzodiazepines, farmapram xanax bars is excreted in human milk.

The safety and efficacy of farmapram xanax bars in patients younger than 18 years has not yet been established.

SECONDARY AND ADVERSE REACTIONS:

 Side effects if they occur are generally observed at the start of therapy and usually disappear with discontinuation of treatment or dose adjustment. The most common side effect with alprazolam was drowsiness.

Less common effects were: lightheadedness, blurred vision, incoordination, gastrointestinal symptoms, autonomic manifestations, headaches, depression, insomnia, fear, variations in body weight and memory / amnesia alterations. As with other benzodiazepines, paradoxical reactions such as stimulation, agitation, difficulty in concentration, confusion, hallucinations or other behavioral effects may occur.

DRUG INTERACTIONS AND OTHER GENDER:

 Benzodiazepines including alprazolam produce additional CNS depressant effects when co-administered with substances such as barbiturates, psychotropic alcohol, anticonvulsant antihistamines, and other drugs which themselves produce CNS depression.

Plasma concentrations of imipramine and decipramine have been reported to increase by an average
of 31 and 20% respectively when administered
concomitantly with doses greater than 4 mg / day of alprazolam. The clinical significance of these changes is unknown.

The pharmacokinetic interaction of benzodiazepines with other drugs has also been reported, as in the case of alprazolam and other benzodiazepine clearance, which can be delayed by co-administration of cimetidine or macrolide antibiotics. The clinical significance of this is not clear.

ALTERATIONS IN THE RESULTS OF LABORATORY TESTS:

They have not been reported to date.

PRECAUTIONS REGARDING THE EFFECTS OF CARCINOGENESIS, MUTAGENESIS, TERATOGENESIS AND ON FERTILITY:

 No potential carcinogenic activity has been observed in rats during 24 months of studies with alprazolam at doses above 375 times the dose in humans.

mexican farmapram bars was not mutagenic in the rat micronucleus test at doses above 1,250 times the human dose. mexican bars 2 mg did not cause impairment of fertility in rats at doses above 62.5 times the dose in humans.

DOSAGE AND ROUTE OF ADMINISTRATION:

 Oral.

The optimal dose of alprazolam should be individualized based on the severity of symptoms and the individual response of the patient.

The average dose meets the needs of most patients; In the case of patients requiring higher doses, these should be carefully established (in order to avoid side effects) and administered by increasing the dose in the afternoon or evening first than that of the most active hours.

In general, patients who have not previously received psychotropic treatment required lower doses than those who have taken minor antidepressant hypnotic tranquilizers or those with a history of chronic alcoholism. It is recommended as a general principle the use of the lowest dose when starting in elderly or debilitated patients to avoid the risk of developing over-sedation or ataxia.

Anxiety states with mexican farmapram bars:

Adults: Usual starting dose: 0.25 to 0.50 mg administered 3 times a day. Usual dose in treatment: 0.50 to 4.0 mg daily: administer in divided doses.

Geriatric or debilitated patients:

Usual starting dose: 0.25 mg.

Usual treatment dose: 0.50 to 0.75 mg daily in divided doses which can be increased if necessary and tolerated. If side effects occur the dose should be reduced.

Alterations related to panic attacks: Start with 0.50 to 1.0 mg provided at bedtime.

The dose should be adjusted according to the patient’s response. Dose adjustments should be in increments of no more than 1 mg every three to four days.

Additional doses may be provided until a dosing schedule of three or four times a day is reached. The average dose in clinical studies was 5.7 ± 2.27 mg with patient cases requiring a maximum of 10 mg daily.

MANIFESTATIONS AND MANAGEMENT OF OVERDOSE OR ACCIDENTAL INGESTION:

The overdose manifestations of mexican bars 2 mg include extensions of its pharmacological activity mainly ataxia drowsiness confusion coordination disorders decreased reflexes and coma.

If present, it is recommended to induce vomiting and / or gastric lavage as in all cases of drug overdose.

Breathing, pulse and blood pressure should be monitored; it must also be supported by general measures when necessary.

Fluids will be administered intravenously and adequate ventilation of the airways will be maintained.

Animal experiments indicate that cardiopulmonary collapse may occur when massive doses of alprazolam are administered intravenously (above 196 mg / kg 2000 times more than the usual maximum dose in humans). Animals can be resuscitated with positive mechanical ventilation and intravenous infusion of levarterenol. Other animal studies suggest that forced diuresis or hemodialysis are probably of little value in the treatment of overdose; the physician should bear in mind that multiple medications may have been ingested.

Leave a Reply

Your email address will not be published. Required fields are marked *

WhatsApp
Hello, we are here for any question, feel free to talk with us
error: Content is protected !!